1. 1. US Partner: Competitor or Complementary Player? 2. Single partner for several applications or multiple partners per each? 3. Funding options for research projects? PCCI January 19, 2009 Diana Mackie, Business Dev. Silvia G Codony, Clinical Research Contura International A/S (Archive Version)

2. Contura Business Units For urinary incontinence Pipeline New applications of soft tissue filler technology For facial augmentation Contura is a medical technology company based in Denmark focused on developing, manufacturing and commercializing soft tissue fillers that enhance the quality of people’s lives

3. 2000: Contura established 2001: Aquamid ® granted the CE-marking for use in soft tissue facial augmentation 2003: Bulkamid ® granted the CE-marking for use in the treatment of female urinary incontinence 2004: Launch of Aquamid ® Reconstruction for lipoatrophy, rhinoplasty and volume correction 2006: FDA grants Aquamid ® I D E, allowing its use in a major comparative clinical trial in the United States 2007: Contura and ETHICON, a J & J company, sign agreement granting ETHICON exclusive worldwide distribution rights for Bulkamid ®. Contura’s United States subsidiary Contura Inc. established Contura awarded the Product Differentiation Innovation Award for Aquamid ® by Frost & Sullivan 2008: Clinical trial of Bulkamid ® in the United States begins New manufacturing facility completed Contura History and Milestones

4. Aesthetic Filler Market Aquamid ® Positioning Aquamid ® Pivotal Clinical Trial Results Partnership Opportunity

5. US Aesthetics Filler Market Total Aesthetics Medicine market size exceeds $13 Billion* –Surgical procedures$ 8.4 B –Non-Surgical procedures$ 4.8 B Non-Surgical Procedures market size, includes MD fees & product –Botox > $ 1 B –All soft tissue fillers $ 1 B Number of Procedures –Botox 4.6 M $350 M at office retail –Soft Tissue Fillers 1.5 M $350 M at office retail * Source: Data from 2007 ASAPS and the May 2008 Millenium Research Group Report

6. Market Dynamics: Many New Introductions 2004 2005 2006 2007 2008 2009 Radiesse Elevess relaunch Restylane Sculptra Juvederm Evolence Artefill (Puragen), Perlane Prevelle ___▼_______▼________________▼_▼_▼_▼______▼_▼_▼▼__________► Sources: industry studies, publications, company information Hyaluronic Acid brands (HAs), Particle and Polymer brands (PPFs), Collagen brand

7. After cannibalizing Collagen, HA growth was blunted. Number of procedures Source: ASAPS (ASPS data show same effect)

8. Competitive Players Portfolio Approach in high gear Allergan: Botox + very successful launch of Juvederm line Mentor: PurTox + Prevelle Silk launch + PLEs (acquired by J&J) BioForm: Radiesse + Relaxed Expressions (RF technique alternative to neurotoxin) Medicis: Neurotoxin + Restylane line Artes Medical: Elevess (HA) + Artefill long duration filler (now in Chapter 7) Bundling promotions is a key factor for success and is believed to help hold physicians loyal to your line.

9. Aesthetic Filler Market Aquamid ® Positioning Aquamid ® Pivotal Clinical Trial Results Partnership Opportunity

10. US Aesthetics Filler Market Total Aesthetics Medicine market size exceeds $13 Billion* –Surgical procedures$ 8.4 B –Non-Surgical procedures$ 4.8 B Non-Surgical Procedures market size, includes MD fees & product –Botox > $ 1 B –All soft tissue fillers $ 1 B Number of Procedures –Botox 4.6 M $350 M at office retail –Soft Tissue Fillers 1.5 M $350 M at office retail * Source: Data from 2007 ASAPS and the May 2008 Millenium Research Group Report

11. Market Dynamics: Many New Introductions 2004 2005 2006 2007 2008 2009 Radiesse Elevess relaunch Restylane Sculptra Juvederm Evolence Artefill (Puragen), Perlane Prevelle ___▼_______▼________________▼_▼_▼_▼______▼_▼_▼▼__________► Sources: industry studies, publications, company information Hyaluronic Acid brands (HAs), Particle and Polymer brands (PPFs), Collagen brand

12. After cannibalizing Collagen, HA growth was blunted. Number of procedures Source: ASAPS (ASPS data show same effect)

13. Competitive Players Portfolio Approach in high gear Allergan: Botox + very successful launch of Juvederm line Mentor: PurTox + Prevelle Silk launch + PLEs (acquired by J&J) BioForm: Radiesse + Relaxed Expressions (RF technique alternative to neurotoxin) Medicis: Neurotoxin + Restylane line Artes Medical: Elevess (HA) + Artefill long duration filler (now in Chapter 7) Bundling promotions is a key factor for success and is believed to help hold physicians loyal to your line.

14. NeurotoxinCollagenHyaluronic Acids Longer Lasting AllerganYES Medicis(Pipeline)YES Mentor + JnJ (Pipeline)YES BioFormRelaxed Expressions YES Artes Medical YES Each company started from one box and has been acquiring to complete the portfolio

15.  Aquamid  characteristics: - Non-degradable - Biocompatible, Non-migrational - Non-allergenic, atoxic - Homogeneous (no particles) - Exchanges water, salts and organic molecules with host tissue - Stored without refrigeration  Mode of Action -Volumizer – No intended foreign body reaction -full integration and vascularization Aquamid Has Unique Properties and Benefits  Aquamid  is an injectable hydrogel consisting of 97.5% water and 2.5% cross-linked polyacrylamide (1 ml syringe/27G needle)

16. Facial skin sags → Surgical Facelift Loss of subcutaneous fat tissue → volume filler “Boosting volume under the skin” Wrinkles & folds in lower face → dermal fillers Lines & wrinkles in upper face → neurotoxins AgeingAgeing Young Old New Trend: Volume Filling and Facial Sculpting

17. Unique Benefits of Aquamid ® Versatile volumizer: well suited for volumizing and sculpting procedures. Directed to the subcutaneous tissue for immediate filling and lifting effect. Natural look and feel: The gel is homogeneous. Aquamid® does not induce inflammatory nodules or granulomas. Integrates completely with existing tissue. Lasting enhancement: non-resorbable and enduring augmentation. Clinical data demonstrate patient and investigator satisfaction that exceeds 90% after 5 years.

18.  Naso labial folds  Lip augmentation  Cheek contouring  Mento labial folds  Glabella filling  Nose correction  Chin augmentation  Scar correction  Facial augmentation to correct lipoatrophy  Minor body contouring Aquamid ® Versatile in Applications

19. Durability of augmentation Compatibility with tissue Evolence Soft Tissue Filler Positionings Artefill SculptraRadiesse Juvederm Restylane

20. Aquamid ® Pivotal US Study Results Study Design Results Highlights –Effectiveness –Safety

21. Study Design Aquamid ® – 210 subjects Restylane ® – 105 subjects Screening Treatment to Optimal Max 3 sessions 3M6M9M12M Treated area: nasolabial folds 13 Sites in the US – each with 19 - 33 subjects

22. Pivotal Study Key Conclusions Successfully show that Aquamid ® is safe and effective for its intended use. Support the regulatory requirements for the PMA filing

23. Market Outlook Flat to low growth through 1H 2009 due to economy and less DTC advertising for next 6 months – however Botox grew by 13% in a challenging Q4/2008 New aesthetic medicines will launch, about one per year. Premium place given to those that leverage a sales force in place and where bundling can occur Aquamid ® launch in 2010 should find an industry in growth again with receptive physicians and consumers.

24. Partnership Opportunity Contura is seeking a US Marketing partner via a US/NA license to commercialize Aquamid ® to its target customers. The framework of a marketing plan is available and shows how Aquamid ® would roll out to experienced and trained physicians in soft tissue fillers Aquamid ® will sustain an appropriate price premium. Supply and further development to come from Contura A/S

25. Other Potential Partners for Aquamid® Beyond Current Filler Competitors Therapeutic Dermatology FocusAesthetic Equipment/Device Focus Galderma Graceway American Laser Angiotech Pharma Merz Nycomed Cynosure New Star Lasers Obagi KIng PhotoMedex Syneron SkinMedica Stiefel Consumer Companies in OTC Derm ValeantP&G J&J DermaPlus DermaVance Schering-Plough Unilever